These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 20298992

  • 1. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G.
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
    Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E.
    J Am Coll Cardiol; 2013 Jan 08; 61(1):23-34. PubMed ID: 23287370
    [Abstract] [Full Text] [Related]

  • 4. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G.
    JACC Cardiovasc Interv; 2012 Mar 08; 5(3):281-9. PubMed ID: 22440493
    [Abstract] [Full Text] [Related]

  • 5. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciascio G.
    Am J Cardiol; 2010 Sep 01; 106(5):619-23. PubMed ID: 20723634
    [Abstract] [Full Text] [Related]

  • 6. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.
    Am J Cardiol; 2007 Jun 01; 99(11):1518-22. PubMed ID: 17531573
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
    Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W.
    Am J Cardiol; 2008 Jun 15; 101(12):1700-3. PubMed ID: 18549843
    [Abstract] [Full Text] [Related]

  • 9. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W.
    EuroIntervention; 2014 Jun 15; 10(2):204-11. PubMed ID: 24952058
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S, Ohlmann P, Jesel L, Radulescu B, El Adraa E, Crimizade U, Wiesel ML, Gachet C, Morel O.
    Atherosclerosis; 2011 Aug 15; 217(2):465-72. PubMed ID: 21524751
    [Abstract] [Full Text] [Related]

  • 13. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, Kim DK, Kim DK, Kim KH, Seol SH, Nam CW, Hur SH, Kim W, Park JS, Kim YJ, Kim DS.
    Int J Cardiol; 2013 Sep 01; 167(5):1877-81. PubMed ID: 22682702
    [Abstract] [Full Text] [Related]

  • 14. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB, Koo BK, Choi WG, Kim SY, Park J, Kwan J, Park CG, Kim HS.
    Clin Ther; 2013 Jan 01; 35(1):28-37.e4. PubMed ID: 23328268
    [Abstract] [Full Text] [Related]

  • 15. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, Capranzano P, Kodali M, Dharmashankar K, Charlton RK, Bass TA, Angiolillo DJ.
    JACC Cardiovasc Interv; 2012 Mar 01; 5(3):293-300. PubMed ID: 22440495
    [Abstract] [Full Text] [Related]

  • 16. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G.
    J Am Coll Cardiol; 2008 Sep 30; 52(14):1128-33. PubMed ID: 18804738
    [Abstract] [Full Text] [Related]

  • 17. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.
    J Am Coll Cardiol; 2014 Mar 25; 63(11):1061-70. PubMed ID: 24486281
    [Abstract] [Full Text] [Related]

  • 18. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.
    Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH.
    JACC Cardiovasc Interv; 2012 Mar 25; 5(3):259-67. PubMed ID: 22440490
    [Abstract] [Full Text] [Related]

  • 19. The STIB score: a simple clinical test to predict clopidogrel resistance.
    Legrand D, Barbato E, Chenu P, Magne J, Vrolix M, Wijns W, Legrand V, STIB investigators.
    Acta Cardiol; 2015 Oct 25; 70(5):516-21. PubMed ID: 26567810
    [Abstract] [Full Text] [Related]

  • 20. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T, Calabrò P, Piscione F, De Servi S, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Mariani A, Taglieri N, Reggiani LB, Bianchi R, De Rosa R, Mariani M, Podda G, Généreux P, Stone GW, Angiolillo DJ.
    JACC Cardiovasc Interv; 2014 Oct 25; 7(10):1117-27. PubMed ID: 25240538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.